Aeterna Zentaris Announces At the Market Issuance Program
March 28 2017 - 5:00PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS):
All dollar amounts are stated in US$
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the “Company”)
announced today that it has commenced a new “at-the-market”
offering pursuant to its existing At Market Issuance (“ATM”) Sales
Agreement, dated April 1, 2016, with H.C. Wainwright & Co., LLC
(the “Sales Agent”), under which the Company may, at its
discretion, from time to time during the term of the ATM Sales
Agreement, sell up to a maximum of 3,000,000 common shares through
ATM issuances on the NASDAQ Stock Market, up to an aggregate amount
of $9.0 million. Any sales made under this ATM program will be made
through the Sales Agent. The common shares will be sold at market
prices prevailing at the time of the sale of the common shares and,
as a result, sale prices may vary.
The common shares will be offered under a new prospectus
supplement no. 3 filed with the United States Securities and
Exchange Commission (the “SEC”) under the Company’s shelf
registration statement on Form F-3 (333-194547) filed with the SEC
on March 14, 2014, which was declared effective by the SEC on March
28, 2014.
The shelf registration statement on Form F-3 and the prospectus
supplement for this offering are available on the SEC’s website
(www.sec.gov). Alternatively, the Sales Agent will provide copies
of these documents upon request by contacting H.C. Wainwright &
Co., LLC, 430 Park Avenue, 4th Floor, New York, NY 10022 at
placements@hcwco.com.
This press release does not and shall not constitute an offer
to sell or the solicitation of an offer to buy any of the common
shares, nor shall there be any sale of the common shares in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We recently completed Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
non-U.S. territories where such out-licensing would enable us to
ensure development, registration and launch of our product
candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value
to our shareholders, employees and the medical providers and
patients who will benefit from our products. For more information,
visit www.aezsinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170328006509/en/
Aeterna Zentaris Inc.Philip A. Theodore, 843-900-3223Senior Vice
Presidentir@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024